Myrexis, Inc. is developing Azixa™ (verubulin, MPC-6827), a new investigational cancer agent, to see if it can provide an effective treatment for people with brain tumors. It is an investigational agent, which means it has not been approved by the Food and Drug Administration (FDA) for marketing.